Targets › FGF2
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2026.
Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signaling. (UniProt, P09038)
Open in Phaseline: the race on FGF2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| D. Bradley Welling, MD, PhD | Fibroblast Growth Factor 2 (FGF2) Fibroblast growth factor 2 (FGF2) promotes cell proliferation and tissue repair | FGF2 | Phase 1 | Chronic Tympanic Membrane Perforation | Dec 2026 |
Chronic Tympanic Membrane Perforation (1)
small molecule (1)
D. Bradley Welling, MD, PhD (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.